Nov. 15, 2012 (GLOBE NEWSWIRE) -- Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, will unveil a national mobile and internet platform for consumers and demonstrate how enterprise imaging solutions support achieving Meaningful Use objectives at the Radiological Society of North America (RSNA) in booth #4845.

The U.S. Food and Drug Administration (FDA) has granted market clearance for the Avinger Inc. Ocelot optical coherenace tomography (OCT) catheter to help cross chronic total occlusions (CTOs) in patients with peripheral artery disease (PAD).

The U.S. Court of Appeals for the Federal Circuit affirmed an April 2010 federal jury decision that Medtronic CoreValve LLC is willfully infringing  Edwards Lifesciences' U.S. Andersen transcatheter heart valve patent. The Appeals Court also ordered the trial court to reconsider Edwards' request for a permanent injunction that would prohibit the manufacture and sale of the CoreValve System in the United States.

The U.S. Patent and Trademark Office has awarded Biomedical Systems U.S. Patent Number 8301236 for its TruVue Wireless Ambulatory ECG Monitoring System.  Biomedical Systems developed TruVue for the diagnosis and management of atrial fibrillation, considered the leading preventable cause of stroke affecting nearly three million Americans at a cost of $26 billion each year. The Centers for Disease Control and Prevention estimates the number of people impacted by atrial fibrillation to grow five times the current rate by 2050.

The U.S. Food and Drug Administration (FDA) granted market clearance for Cook Medical’s Zilver PTX drug-eluting peripheral stent. It is the first device of its kind on several fronts to go before FDA review. It is the first drug-eluting stent (DES) for peripheral leg vessels, the first self-expanding DES and the first DES that does not use a polymer to load and elute its drug.

November 14, 2012 — Vital Images received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for 3-D viewing through its universal viewer, VitreaView. The company also released tablet viewing capabilities for VitreaView.

November 14, 2012 — Medtronic Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Valiant Captivia stent graft system for the endovascular repair of isolated lesions (excluding dissections) of the descending segment of the thoracic aorta.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now